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Abstract
Background—Memory loss is an independent predictor of mortality among heart failure (HF) 
patients. Twenty-three to 50% of HF patients have comorbid memory loss but few interventions 
are available to treat the memory loss. The aims of this three-arm randomized controlled trial are 
to: 1) evaluate efficacy of computerized cognitive training intervention using BrainHQ to improve 
primary outcomes of memory and serum brain-derived neurotrophic factor (BDNF) levels and 
secondary outcomes of working memory, instrumental activities of daily living, and health-related 
quality of life among HF patients; 2) evaluate incremental cost-effectiveness of BrainHQ; and 3) 
examine depressive symptoms and genomic moderators of BrainHQ effect.
Methods—A sample of 264 HF patients within four equal sized blocks (baseline cognitive 
function normal/low and gender) will be randomly assigned to: 1) BrainHQ; 2) active control 
computer-based crossword puzzles; and 3) usual care control groups. BrainHQ is an 8 week, 40-
hour program individualized to each patient’s performance. Data collection will be completed at 
baseline and at 10 weeks, 4 months and 8 months. Descriptive statistics, mixed model analyses, 
and cost-utility analysis using intent-to-treat approach will be computed.
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Conclusions—This research will provide new knowledge about efficacy of BrainHQ to improve 
memory and increase serum BDNF levels in HF. If efficacious, the intervention will provide a new 
therapeutic approach that is easy to disseminate to treat a serious comorbid condition of HF.
Keywords
computerized cognitive training; cognitive dysfunction; brain-derived neurotrophic factor; 
apolipoprotein (APOE)-ε4
Among the 6.5 million Americans with heart failure (HF),1 23 to 50% have comorbid 
cognitive dysfunction, including memory loss likely resulting from cerebral hypoperfusion 
and injury to the hippocampus and related structures.2–7 Pressler and colleagues2 found that 
among 249 HF patients 23% had memory dysfunction and 19% had working memory 
dysfunction. Memory is a foundational cognitive process central to survival and well-being. 
Memory loss interferes with patients’ ability to perform instrumental activities of daily 
living (IADL) that are essential for independent living,8 diminishes health-related quality of 
life (HRQL),9 and independently predicts mortality10 and cardiovascular events.11,12
Despite high prevalence and severe consequences of memory loss in HF, there are no widely 
accepted evidence-based therapies to improve memory in HF patients.13 Prior to the 
publication of our preliminary work,14,15 there were few studies in which interventions were 
tested to improve memory in HF that had potential for widespread dissemination16–21 and 
these studies were limited by not targeting memory,16–21 lack of control groups,16–18,20 lack 
of inclusion of variables that may moderate intervention effect (e.g., depressive symptoms, 
genotype),16–21 and small, primarily male samples.16–19,21 In addition, apart from our 
preliminary study,15 none of these intervention studies measured depressive symptoms or 
serum or genomic biomarkers to evaluate intervention response and determine which 
patients might benefit the most from this intervention.
The purpose of this article is to present the design and rationale of the three-arm randomized 
controlled trial titled “Cognitive Intervention to Improve Memory in Heart Failure Patients” 
(MEMOIR-HF). Previously, in two randomized controlled pilot studies (n = 40 and n = 27 
HF patients)14,15,22 preliminary evidence was found of efficacy and incremental cost-
effectiveness when using the scientifically based, easily disseminated, computerized 
cognitive training program Brain Fitness, now part of BrainHQ.23 In these studies, HF 
patients who completed training had improved delayed recall memory (effect size [ES] = 
0.75),14 improved working memory (ES = 0.64),15 and a trend of lower healthcare costs 
($3821 vs $7730)22 12 weeks after baseline. In addition, patients who completed training in 
the second preliminary study had increased (improved) serum brain-derived neurotrophic 
factor (BDNF) levels (ES = 1.21),15 A full-scale efficacy study will now be conducted 
among a larger, more diverse sample of HF patients without a diagnosis of dementia.
MEMOIR-HF has three specific aims and six hypotheses. Aim one is to evaluate the efficacy 
of BrainHQ among HF patients. Aim one hypotheses are:
Compared with active control and usual care control groups, HF patients who receive 
BrainHQ will have greater improvement over time (10 weeks, 4 and 8 months) in:
Pressler et al. Page 2
J Cardiovasc Nurs. Author manuscript; available in PMC 2019 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
H.1.1. delayed recall memory (primary outcome);
H.1.2. (increased) serum BDNF levels (co-primary outcome);
H.1.3. working memory (secondary outcome);
H.1.4. instrumental activities of daily living (secondary outcome); and
H.1.5. health-related quality of life (secondary outcome).
Aim two is to evaluate the incremental cost-effectiveness of BrainHQ among HF patients. 
The aim two hypothesis is: H.2.1. Using an 8-month time horizon and from societal and 
healthcare payer(s) perspectives, BrainHQ will be a cost-effective option in terms of dollars 
per quality-adjusted life years (QALYs) gained compared with control groups at a 
willingness to pay of $50,000 per QALY. Aim three is an exploratory aim to examine 
depressive symptoms, BDNF genotype of the Val66Met polymorphism, and apolipoprotein 
(APOE)-ε4 allele as moderators of BrainHQ effect on primary and secondary outcomes.
Methods
Study Design
The MEMOIR-HF study (R01 NR016116; Clinical Trials.gov identifier NCT 03035565) is a 
three-arm randomized controlled trial designed to compare computerized cognitive training 
using BrainHQ (commercially available from Posit Science) with computerized general 
cognitive stimulation with crossword puzzles (active control) and usual care with no 
computerized cognitive stimulation (usual care) among 264 patients with HF (Figure 1). The 
study was approved by the university institutional review board. All patients will provide 
written informed consent prior to any data collection.
Study Population
The sample will be 264 men and women with HF recruited from multidisciplinary HF and 
cardiology outpatient clinics at a large health system and a small health system in the 
Midwest. Inclusion and exclusion criteria are presented in Table 1. The criteria were 
developed to ensure that enrolled patients have HF, are receiving guideline-derived medical 
therapy based on national clinical practice guidelines, can complete the computerized 
interventions, and do not have a diagnosis of dementia or other known major causes of 
memory loss. The rationale was established for the exclusion criterion cutoff score of MoCA 
< 19 based on empirical data24 and preliminary studies.14,15 Trzepacz and colleagues24 
evaluated sensitivity and specificity of MoCA cutoff scores to detect mild cognitive 
impairment. The sample was 618 cases from the Alzheimer Disease Neuroimaging Initiative 
(ADNI-GO and ADNI-2) databases and included 219 cognitively healthy control 
participants, 299 participants with mild cognitive impairment, and 100 participants with 
Alzheimer Disease. A MoCA score of < 19 was identified by Trzepacz and colleagues as 
appropriate to use as a screening cutoff because it would allow for inclusion of as many 
people as possible with mild cognitive impairment but not dementia. A MoCA score of < 19 
had sensitivity of 87.3 and specificity of 77.0 for detecting mild cognitive impairment.24 In 
addition, in preliminary studies14,15 patients with a MoCA score < 19 were unable to 
complete the computerized cognitive training intervention. Patients will be excluded from 
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MEMOIR-HF if they are unable to complete the MoCA because of deficits in visual or 
motor skills. To ensure that patients with likely or diagnosed dementia will be excluded, 
medical records will be reviewed for any diagnosis of dementia, patients’ physicians will 
verify eligibility, and if needed, data will be discussed by members of the research team 
including the neuropsychologist (BG).
Sample Size Justification and Power Analysis
Power analyses were conducted based on data from preliminary studies14,15,22 to determine 
the required sample size to test all hypotheses. The measure of effect size (ES) was Cohen’s 
d. Cohen defined a small ES as d=0.2, a medium ES as d=0.5, and a large ES as d=0.8.25 
MEMOIR-HF was designed to have at least 90% power to detect effects of the size observed 
in the preliminary studies for memory14 and serum BDNF15 and 70 to 96% power for 
secondary outcomes.14,15,22 Assuming 20% attrition, enrollment of 264 patients will result 
in 70 patients per group (total 210) at study completion. The minimum detectable effect size 
with 80% power in a sample size of 70 per group is 0.48 (smaller than those reported in 
preliminary studies).
Randomization and Stratification
Enrolled patients will be randomized within four patient blocks to assign patients to the 
three intervention groups (computerized cognitive training, puzzles, or usual care).26 The 
four blocks will be constructed based on baseline cognitive function (Montreal Cognitive 
Assessment test [MoCA] score normal ≥ 26 and low 19–25)11.27,28 and gender. This method 
will result in four blocks: women with normal cognitive function MoCA 26 to 30, men with 
normal cognitive function MoCA 26 to 30, women with low cognitive function less than 
MoCA 26, and men with low cognitive function less than MoCA 26. Patients in each block 
will be assigned to one of three groups with equal probability. A computer-generated 
randomization list will be maintained on a secure website and accessed by the project and 
data managers to determine group assignments after baseline assessment.
Evidence is lacking about which HF patients derive the most benefit from BrainHQ. It is 
unknown if patients with different levels of baseline cognition have similar improvement 
with BrainHQ. Therefore, rationale was established for stratification of MoCA ≥ 26 (normal 
cognitive function) and 19–25 (low cognitive function) based on empirical data from two 
previous studies.11,29 Hawkins and colleagues29 evaluated validity of the MoCA by 
comparing it with a valid neuropsychological test battery among 106 HF patients (49.1% 
men; mean age 68.13 years; NYHA class 1, 2, 3, and 4). In Hawkins’ cross-sectional study, 
the sample mean and standard deviation for the MoCA was 23.18 and 3.9, respectively. 
Hawkins found that a MoCA score of < 25 had optimal sensitivity (0.64) and specificity 
(0.66). Using the MoCA score, patients were classified correctly 65% of the time. Gelow 
and colleagues11 evaluated cognitive dysfunction as measured by the MoCA as a predictor 
of cardiovascular risk events at 180 days. In Gelow’s prospective study, the sample was 246 
HF patients (62.2% men; mean age 56.5 years; NYHA class 2, 3, and 4; EF < 40% in 80.3% 
of sample). The sample mean and standard deviation for the MoCA was 25.9 and 2.6, 
respectively. Ninety-one (37%) of the patients had a MoCA score < 26. A MoCA score < 26 
independently predicted cardiovascular event risk at 180 days after adjusting for HF severity 
Pressler et al. Page 4
J Cardiovasc Nurs. Author manuscript; available in PMC 2019 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
measured by the Seattle HF Model Score and comorbidity measured by the Charlson 
Comorbidity Index. The MoCA score of < 26 was selected because of the prospective design 
and larger sample in the study by Gelow and colleagues.
The rationale for stratification by gender was based on previous HF studies. Although 
women have similar risk for developing HF, women have been under-represented in HF 
studies. In a review of 264 studies published in 2013 in 11 peer-reviewed journals, the mean 
percentage of women in the samples was 32% across 129 studies with original data and 34% 
across 135 studies with data obtained from existing datasets.30 The median percentage of 
women was 29% across the 264 studies. In regards to cognitive dysfunction in HF, men may 
have more cognitive dysfunction than women. In a past study among 249 HF patients, men 
had poorer memory scores than women.2 It is unknown if women and men have similar 
improvements with BrainHQ. Therefore, patients will be stratified by gender.
Computerized Cognitive Training Intervention
In MEMOIR-HF, the intervention will be the six BrainHQ exercises used in the preliminary 
studies: 1) Sound Sweeps, 2) Fine Tuning, 3) Memory Grid, 4) Syllable Stacks, 5) To-Do 
List Training, and 6) In the Know. Patients will be given a laptop computer and if needed, 
internet access with a mobile internet card to perform BrainHQ. They will be taught to 
perform the intervention 1 hour per day, 5 days per week for 8 weeks for a total of 40 hours.
The computerized cognitive training intervention using BrainHQ was selected for 
MEMOIR-HF based on scientific rationale and empirical literature. BrainHQ is guided by 
knowledge of neurogenesis and neuroplasticity.23,31–34 Neurogenesis occurs in the 
hippocampus after injury and the hippocampus may be damaged in HF.31–34 Woo, Kumar, 
and colleagues7,35,36 documented neuronal loss and loss of axonal integrity in multiple areas 
of the brain of HF patients when compared with control participants, including the 
mammillary bodies, fornix, and hippocampus which are part of the memory structures of the 
brain. Neurogenesis and neuroplasticity are mechanisms through which the brain may 
recover from events (e.g., small or silent infarcts) and compensate for oxygen deprivation.
31,32
 There is promising evidence that intensive training designed to increase sensory 
stimulation and perform cognitively challenging activities promotes neuroplasticity and 
improves memory.37–39
BrainHQ provides core elements which are necessary for inducing neuroplasticity (Table 2). 
The six core elements are: 1) intensive and progressive training of the auditory system, 2) 
processed speech, 3) behavioral tracking, 4) working memory training, 5) attentive listening, 
and 6) response feedback and rewards. Intensive training (defined as 1 hour per day, 5 days 
per week for 8 weeks, for a total of 40 hours) provides repetitive practice that is necessary to 
improve precision and accuracy in understanding speech which may improve recall. 
Progressive training provides exercises that are increasingly complex as the person 
progresses through the program. Speech used in the program is processed by an algorithm 
that increases the rate and complexity of speech over the training sessions to enhance the 
person’s ability to understand and encode speech. Behavioral tracking is used to monitor 
individual performance and ensure that the person is training at a threshold level that is at 
the uppermost level of his/her skill. This threshold training is a unique element because it 
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tailors training to the person’s performance. Working memory training is incorporated 
because it is central to memory formation. For example, attentive listening is incorporated 
by requiring the person to press the start button to begin each exercise, which assists in 
focusing. Finally, feedback and rewards provided in the program may strengthen learning.
37,39
The ability to encode, recall, and use information obtained through speech is closely linked 
to the ability to hear and interpret speech accurately. BrainHQ was developed to improve a 
person’s ability to hear speech and thereby improve ability to encode, recall, and use 
information. Refining listening skills to more clearly distinguish individual sounds that are 
part of speech improves recall. Recall of information is quicker and more accurate. The 
emotional context of auditory information that is received influences a person’s ability to 
recall the information. Events associated with surprise and stronger emotions are more novel 
and easier to recall.40 BrainHQ incorporates surprising and novel content to strengthen 
recall.
Previously, in the Advanced Cognitive Training for Independent and Vital Elderly 
(ACTIVE) Trial, Ball and colleagues found that a non-computerized cognitive training 
intervention improved memory, processing speed, reasoning, IADL, and HRQL performance 
among 2,832 healthy elders.41–42 In the ACTIVE trial, Wolinsky found that risk of HRQL 
decline was reduced by 38% at 2 years (p = .004)42 and the annual predicted healthcare 
expenditures declined by $223 (p = .024) at 1 year post-intervention for the group trained in 
reasoning.44
The ACTIVE Trial served as the basis for a computerized cognitive training intervention 
tested by Mahncke and colleagues among 182 healthy older adults.37 Adults who completed 
the program had significant improvements in memory compared with adults in attention 
control and no-contact groups.37 In a multisite double-blind randomized controlled trial of 
this intervention among 487 older adults, Smith and colleagues found that memory and 
working memory improvement was significantly greater in adults who received Brain 
Fitness (now BrainHQ) than in adults who received general cognitive stimulation.38 Brain 
Fitness was efficacious in studies among 79 older adults,45 4746 and 1247 persons with mild 
cognitive impairment, 32 persons with schizophrenia,48 and 17 HF patients,21 but studies 
were limited by small samples.
The mechanism by which computerized cognitive training using BrainHQ improves memory 
is undetermined. One potential mechanism is that training increases serum levels of the 
pleiotropic neurotrophin BDNF. BDNF, a growth factor widely distributed throughout the 
brain, exerts multiple effects in the brain during and after development. It is involved in 
regulation of synaptic plasticity and promotion of survival of neurons that influence learning 
and memory by modulating hippocampal plasticity in the adult mammalian nervous system.
49
 In a randomized controlled study among 56 persons with schizophrenia, compared with 
26 persons who received an active control intervention of computer games, 30 persons who 
completed 50 hours of computerized cognitive training using BrainHQ had significantly 
increased serum BDNF levels at 2 weeks (p = .03) and 10 weeks (p = .02) after training.50 
Moreover, among the 30 persons in the BrainHQ group, serum BDNF levels normalized 
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after 10 weeks and increased serum BDNF was associated with improved quality of life (p 
= .01). The investigators concluded that serum BDNF may be a peripheral biomarker that is 
responsive to the effects of cognitive training and potentially other cognitive enhancement 
interventions in persons with schizophrenia. In our preliminary study,15 compared with 9 HF 
patients who did not complete cognitive training, 11 HF patients who completed 40 hours of 
cognitive training using BrainHF over 8 weeks had significantly increased serum BDNF 
levels (p = .011). Taken together, these studies support the need for further investigation and 
suggest that increased BDNF may contribute to or underlie the improvements observed in 
memory performance after computerized cognitive training using BrainHQ.
Rationale for Control Groups
Active Control Group—Patients who are randomly assigned to the active control group 
will receive a computer-based intervention using crossword puzzles. This intervention 
consists of a series of crossword puzzles that are available from Internet sites that are free to 
users. They are visually appealing, have features for solving the puzzles, and come from 
multiple sources. A menu of puzzles will be provided for patients or they may select their 
own. Patients will be given a laptop computer and if needed, internet access using a mobile 
internet card to perform the puzzles intervention. They will be instructed to perform the 
intervention by working on the puzzles 1 hour per day, 5 days per week for 8 weeks for a 
total of 40 hours to match BrainHQ time.
The rationale for this intervention is the belief that increased general cognitive activity 
maintains or improves cognitive function. Performing general cognitively stimulating 
activities may promote plasticity, but it may not be powerful enough to overcome the 
existing brain pathology that accompanies HF. There is limited evidence that completion of 
general interventions such as crossword puzzles generalizes to specific cognitive abilities 
such as memory. This intervention was designed to be consistent with the common 
recommendation from providers to stay cognitively active and to match time spent on 
BrainHQ and computer use.
Usual Care Group—Patients who are randomly assigned to the usual care group will 
continue to receive usual care based on national HF guidelines13 but will not receive any 
specific computerized cognitive interventions from the research team. This group is 
necessary because: 1) it controls for internal validity threats that may occur if only using 
BrainHQ and active control interventions; 2) it is hypothesized that BrainHQ is better than 
usual care; and 3) there are no guideline recommendations for cognitive training for HF.51 
Patients in this group will be offered BrainHQ after study completion at equivalent 
subscription cost.
Measures
All measures have documented validity and reliability among older adults. Data will be 
collected by trained interviewers. Neuropsychological tests will be administered by a tester 
trained by research team members, including a neuropsychologist. Neuropsychological tests 
will be completed in isolated rooms without external distractions at the patients’ homes or at 
the school of nursing neuropsychological testing room.
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Primary Efficacy Outcome Variables
The primary efficacy outcome variables will be delayed recall memory and serum BDNF 
(Table 3). Delayed recall memory will be measured using the Hopkins Verbal Learning Test 
– Revised Version52,53 during face-to-face interviews conducted at patients’ homes at 
baseline, 10 weeks, and 4 and 8 months after baseline. Serum BDNF will be measured 
within two weeks of the face-to-face interviews at baseline, 10 weeks, and 4 and 8 months 
after baseline.
Secondary Efficacy Outcomes Variables
The secondary outcomes will be working memory, IADL, HRQL, and cost-effectiveness 
(Table 3). Changes in working memory will be measured using the CogState Health One 
Back Accuracy Task54,55 at baseline, 10 weeks, and 4 and 8 months after baseline. Changes 
in IADL will be measured using the Everyday Problems Test56 at baseline, 10 weeks, and 4 
and 8 months after baseline. Changes in HRQL will be measured using the Minnesota 
Living with Heart Failure Questionnaire57 at baseline, 10 weeks, and 4 and 8 months after 
baseline. The cost-effectiveness of the computerized cognitive training intervention will be 
evaluated using data on: 1) time spent by research assistants training and delivering the 
interventions; 2) time spent by patients learning and completing interventions; 3) healthcare 
resource use retrieved from the electronic health record; and 4) Health Utilities Index Mark 
358 completed at baseline, 10 weeks, and 4 and 8 months after baseline.
Potential Moderating Variables
Three potential moderating variables of the effect of computerized cognitive training using 
BrainHQ will be examined: depressive symptoms, BDNF gene Val66Met polymorphism, 
and APOE-ε4. Depressive symptoms may occur in HF patients and influence patients’ 
responses to cognitive training. Therefore, depressive symptoms will be evaluated as a 
moderating variable to deepen understanding of whether patients with high depressive 
symptoms have different responses to BrainHQ than patients with few or no depressive 
symptoms. The Patient Health Questionnaire-8 (PHQ-8)59 will be used to measure 
depressive symptoms.
BDNF gene Val66Met polymorphism influences hippocampal neuronal integrity, learning, 
and memory. The abnormality in BDNF gene termed Val66Met polymorphism was linked to 
learning and memory disorders in past studies60–62 and will be evaluated as a potential 
moderating variable that may influence patients’ response to cognitive training. Cherran and 
colleagues63 reported that 35% of White persons have BDNF Val66Met polymorphism. 
Lang and colleagues64 reported that 30.7% of 114 healthy adults in Germany had BDNF 
Val66Met polymorphism. Feher and colleagues65 reported that 41.2% of 160 persons with 
Alzheimer’s disease had BDNF Val66Met polymorphism. In the preliminary MEMOIR-2 
study,15 eight (32%) of 25 HF patients had BDNF Val66Met polymorphism.
APOE-ε4 allele is a risk factor for late-onset Alzheimer’s disease that is associated with 
decreased learning and memory.66–69 Presence of APOE-ε4 allele will be evaluated as a 
potential moderating variable that may influence responses to cognitive training. Farrer and 
colleagues conducted a meta-analysis and found that the frequency of the APOE-ε4 allele 
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was 36.7% among White persons with Alzheimer Disease, 32.2% among African American 
persons with Alzheimer Disease, 13.7% among White persons without Alzheimer Disease or 
other major neurological diseases, and 19.0% among African American persons without 
Alzheimer Disease.69 Bertram and colleagues70 found that the presence of one APOE-ε4 
allele was associated with 4.3 times greater odds of developing late-onset Alzheimer’s 
disease and the presence of two APOE-ε4 alleles was associated with 15.6 times greater 
odds of developing late-onset Alzheimer’s disease. Cordes and colleagues71 reported earlier 
onset of Alzheimer’s disease when compared with persons without APOE-ε4 allele. Finally, 
Vogels and colleagues71 reported that 33% of 62 HF patients in the Netherlands had at least 
one copy of the APOE-ε4 allele. In the preliminary MEMOIR-2 study, 7 (24.1%) of 29 HF 
patients had APOE-ε4 allele,73 potentially increasing their risk for memory disorders and 
altering their responses to cognitive training interventions.
Sample Description Variables and Covariates
Demographics, HF-related clinical variables, medical comorbidities, daytime sleepiness, and 
balance and history of falls will be measured to provide a description of the sample and 
identify potential covariates (Table 3). Measures of premorbid intellect, visual recognition 
memory, attention, psychomotor function, and executive function will be measured to 
provide a more complete description of cognitive function, assist in interpretation of 
outcome measures of delayed recall memory and working memory, and as possible 
covariates.
Intervention Treatment Fidelity
Recommended best practices strategies will be implemented to ensure treatment fidelity.74 
To ensure fidelity for study design, the BrainHQ and active control interventions will be 
delivered for the same length of time (5 hours/week × 8 weeks = 40 hours) and by computer 
platform. To ensure fidelity for provider training, intervention RAs will be trained carefully 
and their performance monitored every 6 months over the study duration. To ensure fidelity 
of intervention delivery, standard size laptop computers will be used for all intervention 
delivery. Interventions delivered by computers offer advantages that strengthen intervention 
delivery and reduce variation in delivery. Stimuli are delivered with precision to all 
participants. Patient responses are measured immediately. The computer quickly adjusts 
exercises to match individual abilities. Training is tailored for each person daily, progress 
tracked, and feedback provided. Interventions are self-directed. Prior computer experience is 
not required.
To ensure fidelity of intervention receipt, intervention research assistants will explain and 
demonstrate interventions to patients, ask patients to give return demonstrations of accessing 
and performing interventions, answer questions, and provide written instructions. They will 
call patients weekly to monitor intervention receipt and time spent using a checklist that will 
be a covariate.
Mental effort used during the intervention performance will be assessed using a structured 
form. BrainHQ and active control group patients will be taught to complete a 4-item 
checklist documenting the mental effort used at the end of each intervention session. 
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Checklists will be used to assess intervention receipt and as a covariate.75 Time spent will be 
monitored using the BrainHQ program and RescueTime software for the active control 
puzzles group and by patient self-report time logs.
Change in clinical condition (dyspnea, fatigue, emotions, and overall health) will be 
monitored weekly during the 8-week intervention phase to ensure that patients’ clinical 
condition is stable and they are able to complete the interventions.76 When the intervention 
research assistants contact patients by telephone weekly, they will assess change in condition 
using a structured questionnaire that will be a covariate. Upon completion of the study, 
patients will complete a satisfaction questionnaire about the program.
Statistical Analysis
Randomization results will be compared to the pre-planned randomization schedule to 
ensure randomization integrity. Descriptive statistics will be completed for all measures. 
Scores will be examined for outliers and appropriate strategies used if needed. Distributions 
based on density plots will be examined. If data are not normally distributed, non-parametric 
methods will be used for analysis. Demographic, clinical, and study variables will be 
evaluated for baseline equivalencies prior to hypothesis testing. Variables (e.g., age, gender, 
smoking status, body mass index, medications) that may influence BDNF interpretation77 
will be evaluated prior to hypothesis testing, although the randomized controlled trial design 
will likely balance these factors. The significance level will be set at < .05 for all analyses.
The primary analyses comparing the three groups will be conducted using the intent-to-treat 
approach in which patients are considered to be in groups to which they have been randomly 
assigned, not on treatment or amount of treatment they actually receive. This approach is 
taken because it is the best method for evaluating potential effects of a treatment policy, 
which is our focus. Another implication of this approach is that patients who are lost to 
follow-up are included, ensuring that observed differences between conditions are not due to 
differential drop out. Use of a mixed model analysis helps achieve this goal.
Analyses for hypotheses testing efficacy of BrainHQ to improve delayed recall memory 
(primary outcome) and serum BDNF levels (co-primary outcome) at 10 weeks, 4 months, 
and 8 months after baseline will use the primary and co-primary dependent measures of 
Hopkins Verbal Learning Test-Revised delayed recall (raw score) and the serum BDNF 
levels. Both dependent variables are quantitative and likely to be normally distributed either 
in raw form or after preliminary transformations. Analysis will be conducted using a mixed 
model analysis78 of repeated measures data including randomization group, time, and 
interactions between group and time while adjusting for the four patient blocks defined by 
baseline cognition and gender using the mixed procedure in SAS. Significant interaction 
between group and time will indicate differences in the changes of delayed recall and BDNF 
levels among the three groups. Following significant interactions of time with treatment 
group, specific contrasts will be tested comparing mean outcome measures in the BrainHQ 
group with each of the other groups at each specific time point after baseline. Analyses for 
testing hypotheses for secondary outcomes are similar to analyses for testing hypotheses for 
primary outcomes and will involve contrasting patients who receive BrainHQ active and 
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usual care groups on improvements in working memory, IADL, and HRQL. Analyses will 
use mixed models as described above.
Analyses related to aim one (all primary and secondary outcomes) will determine whether 
effect of BrainHQ differs by level of baseline cognitive scores (MoCA score normal ≥ 26 or 
low 19–25) or gender. Interactions between baseline cognitive function and time and 
between gender and time will be added to the mixed model analyses. Key tests are the 
product terms that will indicate whether effects of treatment differ by level of baseline 
cognitive function or gender. Means of outcome measures by treatment group and by time 
will be examined.
Some secondary analyses related to aim one will step outside of the intent-to-treat approach 
by determining whether patients received the recommended dosage of the computer 
interventions. Time spent in training will be analyzed using continuous time data. Because 
HF severity, comorbidities and change in condition may prevent some patients from 
adhering to interventions, New York Heart Association class, Charlson Comorbidity Index 
and change in condition will be tested as potential predictors of number of hours completed 
and as covariates in the analyses of outcomes. With reasonable variability, the analyses will 
be critical in showing whether these variables predict amount of time spent completing the 
intervention and influence outcomes.
Aim two is to evaluate cost-effectiveness of the BrainHQ training intervention. All costs will 
be reported in a standard currency, such as 2016 U.S. dollars. To test the hypothesis, 
incremental cost-effectiveness ratios (ICERs) will be computed using the formula: (C1 − 
C2)/(E1 − E2). C1 equals cost associated with the training intervention, C2 equals cost 
associated with the control group (either active control puzzles or usual care), E1 equals the 
QALYs associated with the training intervention, and E2 equals the QALYs associated with 
the control group. To account for the inherent uncertainty associated with both measures of 
utility and costs, probabilistic cost-effectiveness acceptability curves will be calculated by 
bootstrapping of ICERs, as has become commonplace in analyses of HF treatments.79
Recommendations of the Panel on Cost-Effectiveness in Health and Medicine will be 
followed where possible.80,81 Time horizon of the analyses is 8 months (study duration) and 
thus, discounting is not applicable and long-term net costs will not be estimated. Univariate 
and multivariate sensitivity analyses will be conducted on all estimations of costs and QALY 
estimates. Mixed model analysis will be conducted on all three quantitative measures: 
estimated costs, QALY, and cost/QALY. Taking the societal perspective, the hypothesis is 
that the training intervention using BrainHQ will be a cost effective option compared with 
the control groups. In fact, based upon the pilot study,22 a net cost savings is hypothesized. 
Taking the third-party perspective, the ICER will be calculated using medical services costs 
as the measure of effectiveness.
Aim three is exploratory to examine depressive symptoms (measured by PHQ-8), BDNF 
gene Val66Met polymorphism, and APOE-ε4 as moderators of BrainHQ efficacy. For 
BDNF gene analysis, patients will be grouped as Met negative (ValVal) or Met positive 
(ValMet and MetMet). For APOE analysis, patients will be grouped into ε4 carriers and 
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non-carriers. The effect of BrainHQ training on all measures in aim one are assessed by the 
interactions of group with time. Analyses for aim three will add PHQ-8, BDNF Val66Met 
polymorphism, and APOE carrier status (separately) and interactions of between treatment 
group and these variables with others in the mixed model. The key tests will be of the 
interactions. Power for determining these interactions may be lower than what was estimated 
for aims one and two, but estimated treatment responses within each subgroup will provide 
preliminary hypothesis-generating data for future studies.
Safety Considerations
The study will follow the Policy of the National Institute of Nursing Research for Data and 
Safety Monitoring of Extramural Clinical Trials. Essential elements of the data and safety 
monitoring plan are procedures for: a) monitoring overall study by Investigators and Safety 
Monitoring Committee; b) monitoring study safety, minimizing research-associated risk, and 
protecting confidentiality of participant data; c) identifying, reviewing, and reporting adverse 
events and unanticipated problems; d) assessing new information and published data that 
may impact safety of participants; and e) interim analyses.
Conclusions
To our knowledge, MEMOIR-HF will be the first adequately powered randomized trial of 
computerized cognitive training among HF patients to date. Findings will provide important 
new knowledge about the efficacy, cost-effectiveness, and potential moderators of a 
scientifically-based, easily disseminated computerized cognitive training program for 
memory loss in HF patients. Importantly, findings will help build the empirical evidence that 
is needed in clinical practice to address the debilitating problem of memory loss that 
negatively affects patients’ survival and quality of life. If efficacious and cost-effective, the 
intervention will provide a new therapeutic approach for HF patients and findings can be 
used to inform health systems to adopt it as an intervention and health insurers to provide 
coverage for this intervention.
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What is New?
• MEMOIR-HF is a three-arm randomized controlled trial to 1) evaluate the 
efficacy of BrainHQ among HF patients, 2) evaluate the incremental cost-
effectiveness of BrainHQ among HF patients, and 3) examine depressive 
symptoms, BDNF genotype of the Val66Met polymorphism, and 
apolipoprotein (APOE)-ε4 allele as moderators of BrainHQ effect on primary 
and secondary outcomes.
• If efficacious and cost-effective, the intervention will provide a new 
therapeutic approach for HF patients which can be used to inform health 
systems to adopt it as an intervention and health insurers to provide coverage 
for this intervention.
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Figure 1. 
Research Design
BDNF, brain-derived neurotrophic factor; HRQL, health-related quality of life; HUI, Health 
Utilities Index; IADL, Instrumental Activities of Daily Living; MoCA, Montreal Cognitive 
Assessment test
Pressler et al. Page 19
J Cardiovasc Nurs. Author manuscript; available in PMC 2019 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Pressler et al. Page 20
Table 1
Inclusion and Exclusion Criteria of the MEMOIR-HF Study
Inclusion criteria
• Age ≥ 21 years
• Understands English
• Has access to a telephone
• Hears normal conversation
• For patients with hearing aids, able to wear and hear through headsets
• Diagnosis of chronic HF, Stage C, New York Heart Association class I, II, or III
• HF diagnosis validated by echocardiography or other method in the past 3 years
• Receiving guideline derived medical therapy
• Written informed consent
Exclusion criteria
• History of drug or alcohol abuse or major psychiatric diagnosis (Axis 1) present before the HF diagnosis
• Alzheimer or other dementia diagnosis or central nervous system degenerative disorder
• Terminal cancer
• Baseline Montreal Cognitive Assessment (MoCA) score of < 19 (adjusted by adding 1 point for patients with highest education ≤ 
12 years) because this score indicates possible dementia
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Table 2
Core Elements of Interventions and Usual Care
Element Computerized Cognitive
Training using BrainHQ
Active Control
Crossword Puzzles
Usual Care
Auditory stimuli Intensive, repetitive training of sounds of 
speech
     None      None
Complexity of stimuli Progressively increased over time; 
synthesized speech
Complexity does not progressively 
increase
     None
Cognitive demand Tailored; Training adjusted by computer to 
85% of individual’s threshold
Not tailored; consistent; not adjusted to 
individual’s threshold
No additional 
demand provided
Working memory (e.g., 
attention)
Training in working memory and directed 
attention with each exercise
No directed attention from 
computerized intervention
No additional 
stimuli provided
Novelty Provided by feedback and rewards; visual 
stimuli and content of program; 
individualized
Some novelty of words may occur; 
feedback and rewards not provided
     None
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Table 3
Variables, measures, and sources of data
Variables Measures Sources
Primary efficacy outcomes
Delayed recall memory Hopkins Verbal Learning Test-Revised52,53 delayed recall 
(parallel versions)
Patient
Serum BDNF Serum Patient
Secondary efficacy outcomes
Working memory CogState Health One Back Accuracy Task54,55 Patient
Instrumental activities of daily living Everyday Problems Test – Cognitively Challenged Version56 Patient
Health-related quality of life Minnesota Living with Heart Failure Questionnaire2,57 Patient
Cost-effectiveness - resource use Cardiology and other outpatient clinic visits, emergency 
department visits, ambulance services, hospitalizations, 
procedures, laboratory tests, medications, outpatient 
treatments, home care
Electronic health record
Cost-effectiveness – quality adjusted life years Health Utilities Index Mark-358,82 Patient
Potential moderating variables
Depressive symptoms Patient Health Questionnaire-82,59 Patient
BDNF gene Val66Met polymorphism N/A Patient
APOE-ε4 allele N/A Patient
Blocking variables
Global cognitive function Montreal Cognitive Assessment test27 Patient
Gender N/A Patient
Sample description variables/Covariates
Demographics Demographics form Patient
HF etiology, duration, BNP, devices, medications N/A Electronic health record
Medical comorbidities Charlson Comorbidity Index83 Electronic health record
Daytime sleepiness Epworth Sleepiness Scale84 Patient
Balance Timed-Up-and-Go test85 Patient
Fall history Falls assessment questionnaire Patient
Premorbid intellect Wide Range Achievement Test, 4th ed. Reading86 Patient
Memory-Visual recognition CogState Health One Card Learning Task54,55 Patient
Attention and psychomotor function CogState Health Identification and Detection tasks;54,55 Digit 
Symbol Subtest87
Patient
Executive function Category fluency (animal, vegetable)88 Stroop test89 Patient
Intervention fidelity variables
Time spent each session Computer program and calendar Computer, Patient
Mental effort after each session Mental effort questionnaire Patient
Change in clinical condition Clinical change rating scale76 Patient
Patient satisfaction with program Patient Satisfaction Questionnaire90 Patient
APOE, apolipoprotein; BDNF, brain-derived neurotrophic factor; BNP, brain-natriuretic peptide; HF, heart failure
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